The Food and Drug Administration Friday released for comment through Dec. 13 a discussion paper on certain novel drug manufacturing technologies with the potential to increase timely access to drugs. 

“Pharmaceutical manufacturers have generally produced drugs at large fixed-location facilities, but some are now developing smaller, mobile drug manufacturing processes that can be deployed to multiple locations, including at the point of care, such as at a hospital or clinic,” FDA said. “These novel distributed manufacturing (DM) and point-of-care (POC) manufacturing technologies have the potential to improve the reliability and robustness of the drug supply chain.”

Related News Articles

Headline
In partnership with AHA and others, Amazon Web Services today announced the AWS Healthcare Accelerator, a virtual four-week mentorship program beginning in…
Headline
AHA today released an infographic on considerations for hospitals developing digital solutions to improve maternal care. Hospitals and patients are…
Headline
The Centers for Medicare & Medicaid Services over the Labor Day weekend will transition to a new email service. As a result, CMS will not be able to send…
Headline
Learn how hospital and health system leaders such as Cyndy Banik Dunlap, vice president of nursing/chief nursing officer for Ascension, are supporting…
#HealthCareInnovation Thursday Blog
Recently, nearly 1,000 health care leaders and changemakers convened at Aspen Ideas: Health, part of the Aspen Institute’s Aspen Ideas Festival, to explore…
Headline
As hospitals and health systems face today’s challenges of ensuring a safe and healing environment for their patients and staff, they must also move health…